|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||117.20 - 120.41|
|52 Week Range||96.70 - 139.72|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||42.91|
|Earnings Date||Feb 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||136.53|
NEW YORK, Jan. 18, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Charles River Laboratories International, Inc. will release fourth-quarter and full-year 2018 financial results and provide 2019 guidance on Wednesday, February 13th, before the market opens.
Charles River Laboratories International, Inc. (CRL) today announced that it is pleased to have been selected as one of 230 companies for the 2019 Bloomberg Gender-Equality Index (GEI), which distinguishes companies committed to transparency in gender reporting and advancing gender diversity. For Charles River, the GEI inclusion affirms the Company’s commitment to maintaining a positive and fulfilling work environment for all employees.
Charles River Laboratories International, Inc. (CRL) and Atomwise, Inc. today announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest. Leveraging Atomwise’s AI technology and Charles River’s integrated drug discovery platform has the potential to significantly streamline the hit discovery, hit-to-lead, and lead optimization process for clients’ research efforts.
# Charles River Laboratories International Inc ### NYSE:CRL View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding CRL is favorable, with net inflows of $11.69 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
NEW YORK, NY / ACCESSWIRE / January 9, 2019 / U.S. equities closed up on Tuesday as market participants await details from the recent negotiations in Washington between U.S. and senior Chinese officials. ...
James Foster became the CEO of Charles River Laboratories International, Inc. (NYSE:CRL) in 1992. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies Read More...
Charles River Laboratories International, Inc. (CRL) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 8th, at 10:00 a.m. PST (1:00 p.m. EST), followed by a question and answer session at 10:30 a.m. PST (1:30 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation and the subsequent question and answer session will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com.
Medpace Holdings is the IBD Stock Of The Day as shares consolidate and its relative strength line approaches recent highs. Medpace Holdings stock is expected to break out at 65.19.
According to the GuruFocus All-In-One Screener, the following health care stocks are popular among guru investors. Warning! GuruFocus has detected 2 Warning Sign with CAH. The company, which provides services and products for hospital systems and physicians' offices, has a market cap of $13.5 billion.
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]
How far off is Charles River Laboratories International Inc (NYSE:CRL) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the Read More...
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Jim Cramer rips through his responses to callers' stock questions, including one on a high-profile bank name that had a volatile day.
PRA Health stock broke out Thursday amid a broad boost for medical research stocks. Medical research stocks are benefiting from inflows into biotechs.
Charles River Laboratories International, Inc. (CRL) announced today that it will present at the Evercore ISI HealthConX Conference in Boston on Thursday, November 29th, at 11:00 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com.
A group of current and former Charles River Laboratories employees is suing the company, alleging that the lab services company has ignored their unequal pay and racial discrimination complaints.
Charles River Laboratories International, Inc. (CRL) today announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research. The most recent Compendium update adds gastric and liver models, as well as new molecular data for leukemia, liver cancer, lymphoma, breast cancer and ovarian cancer.
Looking at Charles River Laboratories International Inc’s (NYSE:CRL) earnings update in June 2018, it seems that analyst forecasts are substantially optimistic, with profits predicted to ramp up by an impressive Read More...
Charles River (CRL) delivered earnings and revenue surprises of 10.87% and 3.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Wilmington, Massachusetts-based company said it had net income of $1.22 per share. Earnings, adjusted for one-time gains and costs, were $1.53 per share. The results surpassed Wall Street expectations. ...